Compare Intel Corp (INTC) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intel Corp vs State Street SPDR S&P Biotech ETF — how do they compare? Intel Corp trades at $105.4 (market cap $566.04B), while State Street SPDR S&P Biotech ETF trades at $153.61 (market cap $10.11B). The key difference: Intel Corp is far larger — about 56× State Street SPDR S&P Biotech ETF's market cap, and Intel Corp pays a 2.24% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Intel Corp for 116 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| INTC | XBI | |
|---|---|---|
Market Cap | $566.04B | $10.11B |
Volume | 118,475,837 | 12,903,266 |
Sector | Technology | Broad Market / Factor |
52-Week High | $140.94 | $169.55 |
52-Week Low | $33.62 | $104.99 |
Typical Hold Time | 116 Days | 37 Days |
Enterprise Value | $586.85B | — |
Dividend Yield | 2.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intel (INTC) trades at $105.75, down 6.52% over the past 24 hours, with a mixed technical picture showing bullish overall signals but bearish moving averages and oscillators. The company reported three consecutive quarterly earnings beats in 2026, with Q2 EPS of $0.42 beating expectations of $0.21. However, Intel faces fundamental challenges with negative net income margins (-19.79%) and elevated valuation ratios (P/E of 904.17), though operating cash flow improved to $9.7 billion in 2025.
Intel's turnaround story shows early signs of progress with strong foundry revenue growth and government support, but profitability remains a concern. The stock offers potential upside to the analyst consensus price target of $111.72, though execution risks in the competitive semiconductor space and high debt levels pose significant challenges for investors seeking sustained recovery.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intel Corp
Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.
Read more on INTC →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
